Position in XERS
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$3,841,025
New position
Shares Held
484,978
first reported quarter
Ownership
0.266%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#41
of 238 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026FIRST TRUST ADVISORS LP holds $670,557,120 across 30 Drug Manufacturers - Specialty & Generic names. XERS ranks #17 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
923,125 | $155,583,487 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
249,056 | $134,946,012 | |
| 3 | ALKS |
Alkermes plc.
|
2,421,016 | $126,861,238 | |
| 4 | ZTS |
Zoetis Inc.
|
1,435,652 | $103,165,952 | |
| 5 | TAK |
Takeda Pharmaceutical Co Ltd
|
2,114,912 | $33,902,039 | |
| 6 | LQDA |
Liquidia Corp
|
301,432 | $24,033,173 | |
| 7 | BCRX |
Biocryst Pharmaceuticals Inc
|
1,120,469 | $11,204,690 | |
| 8 | AMRX |
Amneal Pharmaceuticals, Inc.
|
614,206 | $10,631,905 |
All Filings in XERS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,841,025 | 484,978 | Shares | Sole | 2026-08-11 | |
| No filing history on record for this holder in this stock. | ||||||